Literature DB >> 1582729

Thymosin alpha one restores murine T-cell-mediated responses inhibited by in vivo cocaine administration.

P Di Francesco1, F Pica, S Marini, C Favalli, E Garaci.   

Abstract

The effects of different in vivo thymosin alpha one (T alpha 1) treatments on T-cell responses inhibited by cocaine abuse were studied. Administration during cocaine treatment promoted a faster recovery of normal natural killer (NK) cell activity after the suspension of abuse. Suspension of cocaine plus repeated T alpha 1 administrations strongly restored NK activity and, interestingly, spleen cells from mice treated with T alpha 1 during and after cocaine administration achieved a very rapid recovery and the greatest stimulation of natural cytotoxicity. This last treatment also restored the cocaine-inhibited specific T-cell response (i.e. allogeneic cytotoxic T-lymphocyte (CTL) generation) and abrogated the cocaine-induced suppression of interferon gamma (IFN-gamma), interleukin 2 (IL-2) and IL-4 production. Finally restoration and induction of thymic cellularity were significant when T alpha 1 was given during and after cocaine administration. The present investigation provides evidence for the first time that thymic hormones could be of potential value in controlling cocaine-induced impairment of T-cell-mediated immunity in the mouse.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582729     DOI: 10.1016/0192-0561(92)90098-6

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  2 in total

1.  Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.

Authors:  Arno Sungarian; Deus Cielo; Prakash Sampath; Nathaniel Bowling; Peter Moskal; Jack R Wands; Suzanne M de la Monte
Journal:  J Oncol       Date:  2010-01-11       Impact factor: 4.375

2.  Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immunosuppressed by morphine treatments.

Authors:  P di Francesco; R Gaziano; I A Casalinuovo; L Belogi; A T Palamara; C Favalli; E Garaci
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.